Condition: Low Grade Endometrial Stromal Sarcoma · Sponsor: Centre Leon Berard
The primary objective is to compare the progression-free survival (PFS) between aromatase inhibitors interruption and aromatase inhibitors maintenance strategies in patients with a locally advanced or metastatic Low Grade Endometrial Stromal Sarcoma (LGESS).
This description comes directly from the study's public registry record.
Séverine METZGER · +33478782786 · severine.metzger@lyon.unicancer.fr
Isabelle RAY-COQUARD, MD PhD · +33478782828 · isabelle.ray-coquard@lyon.unicancer.fr
Always discuss trial participation with your own doctor first.
| CHU Besançon | Besançon, France | Recruiting |
| Insitut Bergonié | Bordeaux, France | Recruiting |
| Centre François Baclesse | Caen, France | Recruiting |
| Centre Jean Perrin | Clermont-Ferrand, France | Recruiting |
| Centre Oscar Lambret | Lille, France | Recruiting |
| CHU Dupuytren | Limoges, France | Recruiting |
| Centre Léon Bérard | Lyon, France | Recruiting |
| Hopital La Timone | Marseille, France | Recruiting |
| Hopital La Timone | Marseille, France | Recruiting |
| Institut Paoli Calmette | Marseille, France | Recruiting |
| Institut de Cancérologie de Montpellier | Montpellier, France | Recruiting |
| Centre Antoine Lacassagne | Nice, France | Not Yet Recruiting |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03624244